Strong Antitumor Activity of Bevacizumab and Aflibercept in Neuroendocrine Carcinomas: In-Depth Preclinical Study

Background: Neuroendocrine carcinoma (NEC) is a rare and very aggressive tumor. It has been greatly understudied, and very little is known about optimal treatment strategy for patients with this disease. The purpose of this study was to evaluate in vivo whether anti-vascular endothelial growth facto...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Neuroendocrinology 2020-01, Vol.110 (1-2), p.50-62
Hauptverfasser:	Rodríguez-Remírez, María, del Puerto-Nevado, Laura, Fernández Aceñero, María Jesús, Ebrahimi-Nik, Hakimeh, Cruz-Ramos, Marlid, García-García, Laura, Solanes, Sonia, Baños, Natalia, Molina-Roldán, Elena, García-Foncillas, Jesús, Cebrián, Arancha
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiogenesis Inhibitors - pharmacology Bevacizumab - pharmacology Carcinoma, Neuroendocrine - drug therapy Cell Line, Tumor Humans Receptors, Vascular Endothelial Growth Factor Recombinant Fusion Proteins - pharmacology Research Article Vascular Endothelial Growth Factors - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!